Yan Jiao | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yan Jiao | Cancer Cell Biology | Best Researcher Award

Dr. Yan Jiao, First Hospital of Jilin University, China

Dr. Yan Jiao is an accomplished Attending Physician and clinical researcher at the First Hospital of Jilin University, specializing in hepatobiliary and pancreatic diseases. With dual degrees—a Bachelor of Medicine and a Ph.D. from Jilin University—Dr. Jiao has combined clinical acumen with deep expertise in bioinformatics and statistical analysis. A prolific researcher, Dr. Jiao has published extensively on topics ranging from liver cancer and immunotherapy to the adverse effects of diagnostic dyes and post-surgical complications. Notably, Dr. Jiao has contributed to scientific integrity through independent verification of published data and has reported anomalies that led to editorial actions. Skilled in R programming and mining public health datasets, Dr. Jiao blends analytical precision with a commitment to improving patient outcomes. Recognized for a meticulous approach to research, Dr. Jiao’s work exemplifies scientific rigor and ethical responsibility, making a compelling case for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Publication Record:
    Dr. Jiao has co-authored over 20 peer-reviewed journal articles in high-impact journals like Scientific Reports, International Journal of Nanomedicine, and World Journal of Gastrointestinal Surgery. The research spans critical fields like liver cancer, gastric cancer, bioinformatics, and surgical safety, demonstrating multidisciplinary excellence.

  2. High Ethical Standards:
    A rare and commendable contribution is Dr. Jiao’s work in scientific integrity—verifying published studies, detecting image manipulation, and triggering investigations into misconduct. This highlights not only academic rigor but also moral responsibility in research.

  3. Bioinformatics Expertise:
    Proficient in R programming and analysis of large public datasets (FAERS, NHANES, TCGA), Dr. Jiao merges clinical insight with data science to generate real-world impact. The capacity to handle complex data with statistical precision is vital in modern medical research.

  4. Clinical & Research Integration:
    As a practicing Attending Physician in hepatobiliary and pancreatic diseases, Dr. Jiao directly applies research outcomes to clinical settings. This dual competency strengthens translational research and improves patient-centered outcomes.

  5. Collaborative Network:
    Dr. Jiao has worked with a wide range of co-authors, showing adaptability and a collaborative spirit. This not only strengthens individual studies but also reflects influence within a broader research community.

🛠️ Areas for Improvement:

  1. Global Research Visibility:
    While Dr. Jiao has a strong publication portfolio, more engagement with global conferences, keynote presentations, and international collaborations would enhance international recognition.

  2. Grant Leadership:
    There is limited information on independent research funding or grant leadership. Applying for and leading funded projects could further establish Dr. Jiao’s credentials as a principal investigator.

  3. First-Author Publications:
    Though a frequent contributor, a higher proportion of first-author or corresponding-author roles would solidify recognition as a lead researcher, particularly in high-impact original studies.

🎓 Education:

Dr. Yan Jiao pursued both undergraduate and doctoral studies at Jilin University, one of China’s top research institutions. From 2011 to 2016, Dr. Jiao earned a Bachelor of Medicine, laying the groundwork in clinical sciences and human biology. Continuing seamlessly into advanced research, Dr. Jiao completed a Ph.D. at the same university from 2016 to 2019, with a focus on hepatobiliary diseases and translational bioinformatics. The doctoral training combined clinical exposure with robust coursework in molecular biology, epidemiology, and data science. This dual qualification reflects a rare integration of frontline medical experience and deep academic inquiry, preparing Dr. Jiao for a career at the intersection of medicine, research, and technological innovation. Throughout academic training, Dr. Jiao demonstrated a strong aptitude for evidence-based medicine and statistical modeling, gaining recognition for a disciplined and inquisitive approach. The education path reflects a trajectory of consistent excellence and interdisciplinary competence.

💼 Professional Experience:

Dr. Yan Jiao currently serves as an Attending Physician at the First Hospital of Jilin University, where the clinical focus lies in hepatobiliary and pancreatic diseases. In this role, Dr. Jiao combines patient care with research initiatives, particularly in liver cancer. Beyond clinical duties, Dr. Jiao is actively engaged in bioinformatics research, utilizing datasets like FAERS, TCGA, and NHANES to uncover patterns in disease and treatment outcomes. With expert-level proficiency in R programming, Dr. Jiao conducts complex statistical analyses and visualizations. A distinct part of Dr. Jiao’s experience involves auditing the scientific literature for data anomalies and image manipulation, contributing anonymously to investigations into research misconduct. This dual role as a clinician and data scientist uniquely positions Dr. Jiao to address both practical and theoretical challenges in healthcare. Dr. Jiao’s professional journey underscores a rare blend of technical skills, ethical vigilance, and medical expertise, reinforcing eligibility for prestigious research awards.

🔬 Research Focus:

Dr. Yan Jiao’s research is deeply rooted in hepatobiliary oncology, with a specific focus on liver cancer diagnosis, treatment strategies, and prognosis modeling. Integrating clinical insights with computational analysis, Dr. Jiao utilizes large public datasets like TCGA, FAERS, and NHANES to examine treatment efficacy, drug safety, and genetic risk factors. A significant thrust of the research lies in immunotherapy, chemoembolization techniques, and the safety of diagnostic agents like Indocyanine Green. Dr. Jiao also explores post-operative complications and gastrointestinal disorders, broadening the scope of clinical relevance. Equally important is the investigation into scientific integrity, where Dr. Jiao’s efforts in identifying manipulated data and statistical inconsistencies have led to editorial scrutiny in major journals. By bridging bioinformatics with hands-on medical practice, the research offers both theoretical advancements and actionable clinical solutions. Dr. Jiao’s focus is future-facing, centered on personalized treatment and real-world data analysis to optimize patient outcomes.

📚 Publications Top Notes:

  1. 📉 Obesity-Surgery is not the end.

  2. 💉 Landscape of transarterial chemoembolization for hepatocellular carcinoma.

  3. 🧬 Immunotherapy for metastatic gastric cancer.

  4. ⚠️ Exploring the dark side of diagnostic dyes – Indocyanine green.

  5. 🧬 Long non-coding RNA HOTAIR in liver cancer cell behavior.

  6. 🧪 Abraxane-related adverse events – FAERS decade-long analysis.

  7. 🧬 Personalized treatment of perihilar cholangiocarcinoma.

  8. 💊 Impact of immunotherapy on liver metastasis.

  9. 🏥 Incisional hernia after laparoscopic colorectal surgery.

  10. 🔍 Intestinal Behçet’s disease: Diagnosis and treatment.

🧾 Conclusion:

Dr. Yan Jiao is a highly qualified and deserving candidate for the Best Researcher Award. With an exceptional combination of clinical experience, research productivity, ethical vigilance, and bioinformatics expertise, Dr. Jiao stands out as a well-rounded and impactful medical scientist. While there is room to further elevate global visibility and leadership in grant-funded research, the current portfolio already reflects excellence in translational science and data-driven healthcare. In conclusion, Dr. Jiao’s contributions are not only prolific but principled—making this nomination both timely and justified.

Sen Wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile: 

Scopus

✅ Strengths for the Award

  1. Extensive Research Background
    Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesis—key areas in translational oncology.

  2. Prolific Publication Record
    He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

  3. Leadership in Funded Projects
    He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

  4. Innovative Impact through Patents
    Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancer—highlighting a strong translational component in his research.

  5. Academic Awards and Recognition
    His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

  6. Collaborative and Interdisciplinary Approach
    His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

📈 Areas for Improvement

  1. International Recognition
    While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

  2. Citations and Real-world Applications
    Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

  3. Expanded Mentorship Role
    There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

🎓 Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicine—preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

🧪 Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

🏆 Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approach—bridging pharmacology, molecular biology, and clinical application—positions him as a dynamic researcher capable of advancing medical science.

📚 Publications Top Notes:

  1. 📘 MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – 🥇 Sole First Author

  2. 📗 p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – 🥇 Sole First Author

  3. 📕 FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – 🥇 Sole First Author

  4. 📙 Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – 🥇 Sole First Author

  5. 📓 Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – 👥 Co-First Author

  6. 📔 PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

  7. 📒 OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolio—spanning publications, funded projects, patents, and recognized awards—shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.

Miroslaw Markiewicz | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Miroslaw Markiewicz | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Miroslaw Markiewicz , Faculty of Medicine, Collegium Medicum, University of Rzeszow , Poland

Mirosław Markiewicz is a distinguished medical professional specializing in hematology, internal medicine, and bone marrow transplantation. With over three decades of experience in the medical field, he holds the title of Professor and has made significant contributions to the advancement of hematopoietic stem cell transplantation (HSCT) and hematological research. He earned his MD from the Medical University of Silesia in 1989, followed by a fellowship in 1990. Throughout his career, he has worked in prestigious institutions such as the Medical University of Silesia, Katowice, Poland, and the Albany Medical College in New York. Professor Markiewicz’s research has led to numerous high-impact publications, and he is known for his expertise in myelodysplastic syndrome (MDS), graft-versus-host disease (GVHD), and treatment outcomes in bone marrow transplantation. His commitment to research and clinical excellence has earned him recognition as a leader in his field.

Publication Profile: 

Orcid

Strengths for the Award:

Prof. Mirosław Markiewicz is a leading expert in the field of hematology, particularly in hematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GVHD), and myelodysplastic syndrome (MDS). His vast clinical experience and academic achievements, including over 114 publications with an impressive impact factor (IF 217.467) and a Hirsch Index of 12, demonstrate his dedication to advancing medical science. Prof. Markiewicz’s research contributions have been instrumental in improving patient outcomes in hematology, particularly in understanding conditioning regimens for HSCT, and exploring genetic and environmental factors in diseases like multiple myeloma. His leadership roles in various institutions and collaborative work with other prominent scientists further underscore his position as a top researcher in his field.

Areas for Improvements:

While Prof. Markiewicz has an extensive publication record, further engagement in multi-disciplinary research approaches could strengthen his contributions to immunotherapy and the intersection of hematology and precision medicine. Additionally, more involvement in international collaborative research projects could expand the global impact of his findings.

Education:

Mirosław Markiewicz completed his academic journey at renowned institutions, beginning with his MD degree from the Medical University of Silesia in 1989. He further enhanced his expertise through a fellowship in hematology in 1990. His early career was focused on internal medicine and hematology, which laid the foundation for his future work in hematopoietic stem cell transplantation. In 2008, he achieved habilitation, the Polish equivalent of a postdoctoral qualification, and in 2015, he attained professorship status. Over the years, Professor Markiewicz has continued to enrich his academic portfolio with numerous research accomplishments. He has worked at several leading medical institutions, including the Medical University of Silesia, Katowice, and the Department of Hematology at the University of Masku. His educational journey reflects an unwavering commitment to advancing knowledge in hematology and improving patient care through clinical and laboratory research.

Experience:

Professor Mirosław Markiewicz boasts an extensive career in hematology and bone marrow transplantation. From 1992 to 2001, he served as an Assistant Professor at the Medical University of Silesia, where he began his work in the Department of Hematology and Bone Marrow Transplantation. He subsequently became the Head of the Department of Hematology at the same institution, a role he held from 2001 to 2017. During this period, he contributed to expanding the scope of hematological care and research in Poland. Between 2017 and 2019, Professor Markiewicz held a prominent position as Head of the Department at the Department of Hematology at Rzeszów University. In 2019, he joined the University of Ransomw, continuing his research and clinical leadership in hematology. His vast clinical experience spans diagnosis, treatment, and transplantation, particularly focusing on myelodysplastic syndrome and acute leukemia, among other complex hematological disorders.

Research Focus:

Professor Mirosław Markiewicz’s research primarily revolves around hematopoietic stem cell transplantation (HSCT), bone marrow transplantation (BMT), and the management of hematological malignancies. His work focuses on the clinical outcomes of hematopoietic stem cell transplantation in patients with myelodysplastic syndrome (MDS), acute leukemia, and other hematologic disorders. Additionally, his research explores graft-versus-host disease (GVHD), a common complication following allogeneic stem cell transplantation, and strategies for its prevention and management. One of his primary areas of interest is the use of novel conditioning regimens, such as treosulfan-based conditioning, and their comparison with traditional therapies in improving patient outcomes. Furthermore, Professor Markiewicz has contributed to studies on the genetic predisposition to hematological cancers and the molecular mechanisms of disease progression. His publications, covering clinical trials, transplant outcomes, and immunological factors, have had a significant impact on the field of hematology and transplantation.

Publications Top Notes:

  1. “Alogeneic hematopoietic stem cell transplantation with CD14-selected CITT cells add-back in high-risk patients” 🧬💉
  2. “Hematopoietic stem cell transplantation with minor biocompatibility antigen disparities” ⚖️🧬
  3. “Treating rapid development of unclassified myeloid lineage acute leukaemia with trisomy 6 and U2AF1 mutation” 🔬⚡
  4. “Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS” 📊🔬
  5. “The role of lifestyle and environmental factors in the pathogenesis of multiple myeloma” 🌱🧬
  6. “Fludarabine-treosulfan versus fludarabine-melphalan conditioning in older AML patients” 🧪💉
  7. “Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma” 🧬📚
  8. “Graft-versus-host disease and survival in patients with MDS after treosulfan- versus busulfan-based conditioning” 🔬🧬
  9. “Profiles of interferon-gamma and interleukin-2 in patients after allogeneic hematopoietic stem cell transplantation” 🧪🧬
  10. “Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes” 💉⚖️

Conclusion:

Prof. Mirosław Markiewicz’s work represents the cutting edge of hematology research, particularly in stem cell transplantation and the treatment of hematologic malignancies. His academic rigor, innovative research, and clinical expertise make him a deserving candidate for the Research for Best Researcher Award.